Denibulin, a novel vascular-disrupting agent, inhibits microtubule assembly reversibly, disrupting tumor vascular endothelial cell cytoskeletons. Denibulin demonstrated tolerability and potential anti-vascular effects, warranting further investigation in cancer therapy.
Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Microtubule/Tubulin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye